Table 1.
Summary of treatment response, PFS, and OS in the studies.
| Studies | Treatment arms | No. | Treatment response at M1 | Treatment response at M3 | Treatment response at M6 | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | ORR | DCR | CR | ORR | DCR | CR | ORR | DCR | HR (95%CI) | HR (95%CI) | |||
| Liang et al. (19) | CSM-TACE | 171 | 13/107 | 77/107 | 96/107 | 16/82 | 63/82 | 68/82 | 9/54 | 38/54 | 48/54 | 0.882 (0.611–1.274) | 0.753 (0.485-1.167) |
| cTACE | 164 | 10/124 | 58/124 | 108/124 | 3/55 | 25/55 | 46/55 | 3/45 | 21/45 | 36/45 | |||
| Duan et al. (20) | CSM-TACE | 38 | – | – | – | 10/38 | 30/38 | 30/38 | 11/38 | 23/38 | 27/38 | – | – |
| cTACE | 48 | – | – | – | 4/48 | 25/48 | 33/48 | 2/48 | 16/48 | 16/48 | |||
| Ma et al. (16) | CSM-TACE | 94 | 7/57 | 40/57 | 52/57 | 9/44 | 32/44 | 34/44 | 5/27 | 20/27 | 24/27 | 0.820 (0.512–1.312) | 0.843 (0.471-1.509) |
| cTACE | 98 | 5/82 | 36/82 | 73/82 | 0/40 | 17/40 | 34/40 | 2/31 | 13/31 | 25/31 | |||
| Zhao et al. (21) | CSM-TACE | 42 | 11/42 | 34/42 | 38/42 | 13/42 | 32/42 | 39/42 | 11/42 | 32/42 | 38/42 | 1.277 (0.659–2.286) | 1.010 (0.524-1.947) |
| cTACE | 47 | 3/47 | 26/47 | 38/47 | 2/47 | 21/47 | 40/47 | 5/47 | 26/47 | 36/47 | |||
| Liu et al. (22) | CSM-TACE | 14 | 1/11 | 8/11 | 10/11 | – | – | – | – | – | – | – | – |
| cTACE | 9 | 0/8 | 1/8 | 6/8 | – | – | – | – | – | – | |||
| Xiao et al. (23) | CSM-TACE | 26 | – | 8/26 | 18/26 | – | – | – | – | – | – | – | – |
| cTACE | 32 | – | 4/32 | 12/32 | – | – | – | – | – | – | |||
| Liu et al. (24) | CSM-TACE | 31 | – | 20/31 | 29/31 | – | 19/31 | 27/31 | – | – | – | – | – |
| cTACE | 40 | – | 18/40 | 36/40 | – | 12/40 | 24/40 | – | – | – | |||
| Li et al. (25) | CSM-TACE | 34 | 19/34 | 30/34 | 33/34 | – | – | – | – | – | – | – | – |
| cTACE | 33 | 12/33 | 25/33 | 31/33 | – | – | – | – | – | – | |||
| Wang et al. (26) | CSM-TACE | 45 | – | – | – | 16/45 | 36/45 | 41/45 | – | – | – | – | – |
| cTACE | 45 | – | – | – | 11/45 | 34/45 | 38/45 | – | – | – | |||
| Zhou et al. (27) | CSM-TACE | 34 | – | – | – | – | – | – | 8/34 | 28/34 | 30/34 | – | – |
| cTACE | 30 | – | – | – | – | – | – | 3/30 | 17/30 | 24/30 | |||
| Xu et al. (28) | CSM-TACE | 32 | – | – | – | 4/32 | 27/32 | 31/32 | – | – | – | – | – |
| cTACE | 26 | – | – | – | 2/26 | 16/26 | 27/26 | – | – | – | |||
| Lin et al. (29) | CSM-TACE | 33 | 9/33 | 20/33 | 28/33 | – | – | – | – | – | – | – | – |
| cTACE | 32 | 7/32 | 14/32 | 20/32 | – | – | – | – | – | – | |||
| Xiang et al. (14) | CSM-TACE | 36 | 4/25 | 17/25 | 24/25 | 3/15 | 15/15 | 15/15 | 3/9 | 9/9 | 9/9 | 0.326 (0.118–0.899) | 0.397 (0.124-1.267) |
| cTACE | 37 | 3/28 | 11/28 | 25/28 | 0/8 | 5/8 | 6/8 | 1/7 | 4/7 | 5/7 | |||
| Wu et al. (30) | CSM-TACE | 24 | – | – | – | 6/24 | 20/24 | 22/24 | 5/24 | 15/24 | 20/24 | – | – |
| cTACE | 30 | – | – | – | 1/30 | 13/30 | 20/30 | 0/30 | 9/30 | 17/30 | |||
| Ou et al. (31) | CSM-TACE | 46 | 0/46 | 14/46 | 31/46 | – | – | – | – | – | – | – | – |
| cTACE | 41 | 0/41 | 5/41 | 22/41 | – | – | – | – | – | – | |||
| Chen et al. (15) | CSM-TACE | 22 | 3/17 | 12/17 | 16/17 | 3/17 | 10/17 | 13/17 | 2/17 | 4/17 | 10/17 | – | – |
| cTACE | 20 | 2/16 | 9/16 | 13/16 | 0/16 | 7/16 | 12/16 | 0/16 | 4/16 | 10/16 | |||
PFS, progression-free survival; OS, overall survival; CR, complete response; ORR, objective response rate; DCR, disease control rate; HR, hazard ratios; CI, confidence interval; CSM-TACE, CalliSpheres® microspheres transarterial chemoembolization; cTACE, conventional transarterial chemoembolization. “-” indicated the missing data.